Abstract
Chemotherapy, targeted therapy and immunotherapy represent standard of care treatment options in patients with head and neck squamous cell carcinoma (HNSCC). Despite this armamentarium, the prognosis of patients with recurrent and/or metastatic disease remains poor.Antibody drug conjugates (ADC) are a novel class of anticancer drugs that are composed by an antibody, a linker and a payload consisting of anticancer drug. Additional important features include the Drug Antibody Ratio (DAR) and the stability of the linker. The aim of ADCs is to deliver conjugated drugs selectively to cancer cells while sparing normal cells.First ADCs were approved for clinical use more than two decades ago, initially for the treatment of hematological malignancies followed by metastatic breast cancer.The most obvious target for ADCs in HNSCC is EGFR, but other targets were investigated as well. Results of clinical trials investigating the safety and efficacy of ADCs in HNSCC will be presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
